shawn kile, MD
Shawn Julian Kile, M.D.
Sutter Neuroscience Institute
Sutter Medical Group, Neuroscience Department
2800 L Street, Suite 500
Sacramento, CA 95816
(916) 454-6850
(916) 454-6800 fax
EDUCATION AND TRAINING:
Cognitive and Behavioral Neurology Subspecialty Training
07/2006-10/2007
University of California, Davis
Neurology Residency, Chief Resident
07/2004-06/2006 (Chief 07/2005-06/2006)
University of California, Davis
Forensic Psychiatry Fellowship
07/2003-06/2004
University of California, Davis
Psychiatry Residency, Neuropsychiatry Track
06/1999-06/2003
University of California, Davis
Medical Degree
07/1995-05/1999
University of Texas Medical Branch
Bachelor of Science, Biology Major
08/1991-06/1995
University of Texas at San Antonio
LICENSE AND CERTIFICATION:
American Board of Psychiatry and Neurology, Board Certified
Diplomate in Neurology
2009-present
Diplomate in Psychiatry and Forensic Psychiatry
2005-2015
Medical Board of California, Licensed Physician
09/2000-present
PROFESSIONAL EXPERIENCE:
Sutter Medical Group, Neurologist, subspecializing in Cognitive Neurology
10/2007-present
Sutter Neuroscience Memory Clinic
established 07/2009-present
Sutter Transition-clinic for Autism and Neurodevelopmental Disorders (S.T.A.N.D.)
established 05/2009-present
Sutter Neuroscience Concussion and Traumatic Brain Injury Clinic
established 09/2012-present
LEADERSHIP EXPERIENCE:
Medical Director of Sutter Neuroscience Institute (Sutter Health Neuroscience Service Line)
08/2017-present
Regional Chair of Adult Neurology for Sutter Medical Group
10/2014-present
Physician Care Center Lead for Sutter Medical Group- Neurology Division
2/2014- 10/2021
Medical Director of Sutter Neuroscience Memory Clinic
07/2009-present
TEACHING ACTIVITIES:
Professor, UC Davis, Department of Neurology
01/2008-present (promoted Full Professor 7/2021)
Preceptor, Sutter Medical Center Sacramento, Family Medicine Residency Program, Neurology Rotations
11/2007-present
Sutter Neurology Case Conference, Organizer/Moderator
2009-present
Sutter Health Neurodegenerative Case Conference, Presenter
2020-present
PUBLICATIONS:
Five-year Outcomes after IVIG for Mild Cognitive Impairment due to Alzheimer Disease
BMC Neuroscience, published August 2021; first author
Reduction of amyloid in the brain and retina after treatment with IVIG for Mild Cognitive Impairment
American Journal of Alzheimer's Disease and Other Dementias, published February 2020; first author
Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer’s disease
Journal of Clinical Investigation, published August 2017
IVIG treatment of Mild Cognitive Impairment due to Alzheimer Disease: a randomized double-blinded exploratory study of the effect on brain atrophy, cognition, and conversion to dementia
Journal of Neurology, Neurosurgery & Psychiatry; published in print February 2017, published ahead of print September 2015; first author
Alzheimer’s Pathology of the Amygdala presenting with Kluver-Bucy Symptoms: An Amygdaloid Variant of Alzheimer’s Disease
Archives of Neurology, published January 2009; first author
Amyloid Clearing Immunotherapy for Alzheimer’s Disease and the Risk of Cerebral Amyloid Angiopathy
Current Research on Alzheimer’s Disease, published 2007; first author
Complex Partial Status Epilepticus in a Patient with Paraneoplastic Limbic Encephalitis associated with Lung Carcinoma
Clinical EEG and Neuroscience, published July 2007; first author
Bithalamic Lesions of Butane Encephalopathy
Pediatric Neurology, published December 2006; first author
Brain Lactate Responses during Visual Stimulation in Fasting and Hyperglycemic Subjects
Psychiatry Research Neuroimaging, published November 2006
Diagnosis and Treatment of Postconcussive Neurobehavioral Symptoms
Continuum, published October 2006; sole author
Neurodevelopmental Pathways to Aggression: A Model to Understand and Target Treatment in Youth
Journal of Neuropsychiatry and Clinical Neurosciences, published August 2006
Pharmacological Intervention for Cognitive Deficits and Aggression in Frontal Lobe Injury
NeuroRehabilitation, published 2006
Neurobehavioral Sequelae of Traumatic Brain Injury
Applied Neurology, published December 2005; first author
Methamphetamine Users in Sustained Abstinence, A Proton Magnetic Resonance Spectroscopy Study
Archives of General Psychiatry, published April 2005
A Dissociation in Attentional Control: Evidence from Methamphetamine Dependence
Biological Psychiatry, published February 2005
Neuroleptic Malignant Syndrome with Dermatological Complications
Journal of Clinical Psychopharmacology, published December 2004
Neuropsychiatric Update: Neuroimaging Schizophrenia
Mental Fitness, published March 2004; sole author
Brain Regions Showing Increased Activation by Threat-Related Words in Panic Disorder
Neuroreport, published March 2003
PRESENTATIONS:
Acute and Chronic Neurologic Complications of COVID-19
Sutter Health Neuroscience Grand Rounds, January 2022
Brain Health Seminar Series
Sutter Neuroscience Institute, November 2017-present
Alzheimer’s Disease Research Update (keynote speaker)
Alzheimer's Association Education Forum, April 2017
Updates in Research for Mild Cognitive Impairment and Alzheimer Disease Dementia
Sutter Neuroscience Annual Symposium, January 2017
IVIG treatment of Mild Cognitive Impairment due to Alzheimer’s Disease
Octapharma Scientific Symposium, Germany, June 2016
Advances in Neurology
Sutter Neuroscience Annual Symposium, March 2015
Alzheimer Disease Research Update (keynote speaker)
Alzheimer’s Coalition Conference, September 2014
Dementia
Alzheimer’s Association Annual Conference, May 2013
Advocating for Care- Communicating with your Physician (moderator/speaker, keynote session)
Alzheimer’s Association Annual Conference, April 2012
Alzheimer’s Disease (keynote speaker)
Alzheimer’s Aid Society Annual Conference, November 2011
The Different Dementias (keynote speaker)
Alzheimer’s Association Annual Conference, March 2010
Dementia with Lewy Bodies
Parkinson Association Northern California; April 2008.
Alzheimer’s Disease, 100-year Update
UC Davis Neurology Department Grand Rounds; June 2006.
AWARDS:
2019 University of California Davis Departmental Award
Awarded by the UC Davis School of Medicine in recognition of service and dedication to the department of Neurology.
2015 Excellence in Volunteer Clinical Faculty Award
Awarded by the UC Davis Neurology Residency Program.
2010 University of California Davis Excellence in Teaching Award
Awarded by the UC Davis Neurology Residency Program.
2006 American Academy of Neurology Resident Award
Awarded by the Graduate Education Committee of the American Academy of Neurology to residents who have demonstrated a commitment to teaching and education in neurology.
2003 University of California Davis Resident Research Award
Awarded by the UCDMC Department of Psychiatry and Behavioral Sciences for recognition of accomplishments in research; first resident at UCDMC to win this award twice.
2002 Rappeport Fellow
Awarded by the American Academy of Psychiatry and the Law to four residents in the United States for recognition of accomplishments in forensic psychiatry.
2001 University of California Davis Resident Research Award
Awarded by the UCDMC Department of Psychiatry and Behavioral Sciences for recognition of accomplishments in research.
VOLUNTEER ACTIVITIES:
UC Davis, Volunteer Clinical Faculty
I volunteer monthly to train neurology residents in the clinical assessment and treatment of neurological disorders at the UCD Neurology Residents’ Clinic.
01/2008-present
RESEARCH EXPERIENCE (in addition to the above publications and abstracts):
New York University/N.I.N.D.S. NeuroCOVID International Registry
Principal Investigator
7/2022-present
APOLLO E4 Trial: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects with Early Alzheimer’s Disease and APOE4/4 Genotype
Principal Investigator
7/2021-present
NEW Imaging Dementia - Evidence for Amyloid Scanning (IDEAS) study
Principal Investigator
08/2020-present
Sutter Health Neurologic Registry for COVID-19
4/2020-present
GRADUATE Trial: A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, and Safety Study of Gantenerumab in Patients with Early (prodromal to mild) Alzheimer’s Disease
Principal Investigator
4/2018-present
The Effect of Intravenous Immunoglobulin on Cerebral and Retinal Amyloid Mild Cognitive Impairment Due to Alzheimer Disease
Principal Investigator (investigator-initiated study)
1/2018-7/2018
Anti-Amyloid treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Principal Investigator
2017-present
Repeatability and Reproducibility of Autofluorescence Measurements by NeuroVision in Normal and Diseased Subjects
Principal Investigator; Sutter Neuroscience Institute in collaboration with Neurovision
3/2017-2018
A Long-term Extension Study of the Safety and Tolerability of RVT-101 in subjects with dementia with Lewy bodies (DLB)
Principal Investigator
08/2017-03/2018
A Phase 2b, Double-Blind, Randomized, Placebo-Controlled Study of RVT-101 in Subjects with Lewy Bodies
Principal Investigator
8/2016-8/2017
Effect of LY3202626 on Alzheimer’s Disease Progression as Measured by Cerebral 18F-AV-1451 Tau-PET in Mild Alzheimer’s Disease Dementia
Principal Investigator
2017-present
Imaging Dementia - Evidence for Amyloid Scanning (IDEAS study)
Principal Investigator
2/2016-12/2017
The Synkinetic Sign: a single-blinded investigation of a novel neurological sign for the early detection of Lewy body/Parkinson disease
Principal Investigator (investigator-initiated study)
11/2014-present
An Open Label, Multicenter Study, Evaluating the Safety and Imaging Characteristics of F18-AV-1451 in Cognitively Healthy Volunteers, Mild Cognitive Impairment, and Alzheimer’s Disease
Investigator
08/2014-01/2018
A Parallel-Group Randomized, Double-Blind, Long Term Safety and Efficacy Trial of MK-8931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer Disease
Principal Investigator
2013-present
A Randomized, Double-blinded, Placebo-controlled Trial of Intravenous Immunoglobulin (NewGam 10%) for Mild Cognitive Impairment due to Alzheimer Disease
Principal Investigator (investigator-initiated study)
2011-present
A Phase III, Randomized, Placebo Controlled, Parallel-Group, Double Blind Clinical Trial of Study Efficacy and Safety Trial of MK-8931 in Subjects with Amnestic Mild Cognitive Impairment Due to Alzheimer’s Disease
Principal Investigator
03/2014-7/2018
A Randomized, Placebo Controlled, Parallel-Group, Double Blind Efficacy and Safety Trial of MK-8931 in Subjects with Mild to Moderate Alzheimer Disease
Principal Investigator
05/2013-8/2017
A Randomized, Placebo-controlled, Blinded, Crossover, Single-Center Study of the Effects of Nuedexta in the Treatment of Neurobehavioral Symptoms of Adults with Autism Spectrum Disorder
Co-Investigator
2012-2016
A Pilot Study to detect A-Beta Plaques utilizing Retinal Imaging System in Alzheimer Disease
Principal Investigator; Sutter Neuroscience Institute in collaboration with Neurovision
2012-2013
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy and Safety Trial of Bapineuzumab in subjects with Mild to Moderate Alzheimer’s Disease (APOE4 Carriers and Non-Carriers)
Sub-investigator
2008-2012
The Ginkgo Evaluation of Memory (GEM) study: a randomized trial of Ginkgo biloba extract in prevention of dementia
Research neurologic examiner; University of California Davis Alzheimer’s Disease Center
2006-2007
Dementia Cohort II Study: Longitudinal Study of Mild Cognitive Impairment
Research neurologic examiner; University of California Davis Alzheimer’s Disease Center
2006-2007
Alzheimer's Disease Neuroimaging Initiative
Research neurologic examiner; University of California Davis Alzheimer’s Disease Center
2006-2007
Double-blind, Randomized, Placebo-Controlled, Clinical Trial of Venlafaxine-ER and Sertraline in the Treatment of PTSD
Sub-investigator; University of California Davis Medical Center
2001-2002
INTERNATIONAL RESEARCH PEER-REVIEW PANEL:
Alzheimer's Association International Research Grant Program, Reviewer
2011-present
NATIONAL AND REGIONAL COMMITTEES:
Sutter Health Education and Research Committee
11/2016-present
Sutter Neuroscience Institute - Neuroscience Clinical Innovation and Research Committee
08/2016-present (Committee Director)
Sutter Neuroscience Research Consortium Executive Committee
Sac-Sierra and Central Valley Regional Lead
9/2014-present
Sutter Medical Group, Regional Quality Management Committee
1/2014-8/2022
Sutter Institute for Medical Research Committee
2012-present
Forensic Neuropsychiatry Committee
American Academy of Psychiatry and the Law
2002-2010
ORGANIZATION MEMBERSHIPS:
American Academy of Neurology
Behavioral Neurology Section Member
American Medical Association
Financial relationships
-
Type of financial relationship:There are no financial relationships to disclose.Date added:06/29/2023Date updated:10/24/2023